

Date: January 28, 2022

The Manager
BSE Limited (DCS- CRD)
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 532039

Dear Sir,

Sub: Outcome of the Board Meeting of Zenotech Laboratories Limited (the Company) held today - Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2021

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today, i.e. Friday, January 28, 2022, have approved and took on record the limited review Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2021, which are enclosed herewith along with the Limited Review Report of the Statutory Auditors of the Company on Standalone Unaudited Financial Results.

The meeting of the Board of Directors of the Company commenced at 5:00 p.m. and concluded at 6:30 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,
For **Zenotech Laboratories Limited**

Lt. Abdul Gafoor

Abdul Gafoor Mohammad
Company Secretary & Compliance Officer



Encl: as above

ZENOTECH LABORATORIES LIMITED

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally (V), Shameerpet (M), Hyderabad - 500078

Phone:+91 90320 44584/585/586 Website: www.zenotechlab.com

Statement of Standalone Unaudited Financial Results for the Quarter and Nine months ended 31 December 2021

		(Rs in lakhs, except share and per equity share data)					
Sl. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue From Operations	925.94	696.20	464.25	2,509.40	1,253.94	1,937.33
II	Other Operating Income	101.80	101.82	99.90	305.39	201.66	307.19
III	Other Income	3.62	3.05	3.64	13.73	10.74	40.84
IV	Total Income (I+II+III)	1,031.36	801.07	567.79	2,828.52	1,466.34	2,285.36
V	Expenses						
	a). Cost of materials consumed	0.01	0.04	0.10	0.05	1.62	3.22
	b). Purchase of Stock-in-Trade	-	-	-	-	-	-
	c). Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	d). Employee benefit expenses	175.10	172.72	155.59	523.71	470.09	649.23
	e). Finance costs	26.98	33.40	46.86	106.73	108.91	154.75
	f). Depreciation and amortization expense	171.75	180.37	171.27	524.55	471.80	645.60
	g). Other Expenses	296.25	319.91	186.75	867.92	653.37	954.07
	Total expenses	670.09	706.43	560.56	2,022.96	1,705.79	2,406.87
VI	Profit/(Loss) before exceptional items and tax (IV-V)	361.27	94.64	7.23	805.56	(239.45)	(121.51)
VII	Exceptional items	-	-	-	-	-	-
VIII	Profit/(Loss) before tax (VI-VII)	361.27	94.64	7.23	805.56	(239.45)	(121.51)
IX	Tax expense						
	a). Current Tax	-	-	-	-	-	-
	b). Deferred Tax	-	-	-	-	-	-
	Total Tax Expense (IX)	-	-	-	-	-	-
X	Profit/(Loss) for the period (VIII-IX)	361.27	94.64	7.23	805.56	(239.45)	(121.51)
XI	Other Comprehensive Income						
	a). Items that will not be reclassified to Profit or Loss						
	Re - measurement of the defined benefit obligations	(0.14)	(0.14)	(1.17)	(0.43)	(3.51)	(0.57)
	b). Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XII	Total Comprehensive Income for the period (X+/-XI)	361.41	94.78	6.06	805.99	(242.96)	(122.08)
XIII	Paid-up equity share capital (Face value of ₹ 10/- per share)	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06
XIV	Reserves i.e. Other equity						(1,262.24)
XV	Earnings/ (loss) per share (of ₹ 10/- each) (not annualised)						
	a). Basic	0.59	0.16	0.01	1.32	(0.39)	(0.20)
	a) Diluted	0.59	0.16	0.01	1.32	(0.39)	(0.20)


See accompanying notes to the financial results

Notes:

- 1 The above financial results for the quarter and nine months ended December 31, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 28th January 2022 and have undergone a 'limited review' by the Statutory Auditors of the Company.
- 2 These financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The impact of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011 and of the various legal proceedings which are currently sub-judice would be made in the financial results of the Company as and when the outcome of the above uncertainties becomes known and the consequential adjustments / disclosures are identifiable / determinable. Accordingly, based on the steps taken by the Company and evidence available so far, any financial impact on the results of the Company is likely to be significantly low.
- 4 The Books of accounts and other related records/documents of the overseas subsidiaries of the Company were missing and due to non-availability of those records/information, complaint before the Hon'ble Economic Offences Court, Nampally, Hyderabad, under the provisions of Section 630 of erstwhile Companies Act, 1956 was filed against the former Managing Director, Late Dr. Jayaram Chigurupati, who was in complete "control over the Company's affairs during the period of those events", which is abated by the court due to demise of the accused. The Company has evaluated and concluded that it is not controlling the US Subsidiary as per Ind AS 110 Consolidated Financial Statements basis its inability to exercise power over the investee. The Company has engaged a consultant in Brazil to file the winding-up applications in adherence to the laws of the country. The Company vide its Board Resolution dated July 25, 2020, has initiated the process of winding-up of its defunct US Subsidiary. Accordingly, the Company is of the view that it does not have subsidiaries within the definition of Ind AS 110 and hence is not required to prepare and present a Consolidated Financial Results.
- 5 The financial results have been prepared on a going concern basis, considering that the Company is well placed to meet the cash burn requirements in the coming periods.
- 6 The Company has evaluated the impact of COVID-19 pandemic on its business operations, liquidity and financial position and based on management's review of current indicators and economic conditions there is no material impact on its financial results as at December 31, 2021. However, the impact assessment of COVID-19 is a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as at the date of approval of these financial results. The Company will continue to monitor any material changes to future economic conditions
- 7 Other operating income includes rentals for the Biotech facility and equipments leased to Sun Pharmaceutical Industries Limited for R&D activities.
- 8 The Company has only one reportable segment, i.e. Pharmaceuticals.
- 9 Figures for previous period/ year have been regrouped wherever required to conform to the current period presentation.

Date: 28th January 2022
Place: Hyderabad

By Order of the Board



Chairman
DIN: 01219312

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company

Review report to the **Board of Directors of Zenotech Laboratories Limited**

1. We have reviewed the unaudited financial results ("the Statement") of **Zenotech Laboratories Limited** ("the Company") for the quarter and nine month ended 31st December 2021, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), which has been initialed by us for identification.

Attention is drawn to note 4 of the Statement which states the reason for non-preparation of consolidated financial results.

2. **Management's Responsibility**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3. **Auditor's Responsibility**

Our responsibility is to express a conclusion on this Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. **Conclusion**

Based on our review conducted, as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the



PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Emphasis of matter:

We draw attention to Note 3 to the Financial results wherein it is stated that the impact of matters relating to several financial and non-financial irregularities pertaining to period prior to 12th November 2011 and of the various legal proceedings which are currently sub-judice would be made in the financial results of the Company as and when the outcome of the above uncertainties becomes known and the consequential adjustments / disclosures are identifiable / determinable. The Company has represented to us that based on the steps taken by the Management and evidence available so far, any financial impact on the results of the Company is likely to be significantly low.

Our conclusion is not modified in respect of this matter.

For **PKF Sridhar & Santhanam LLP**

Chartered Accountants

Firm Registration No. 003990S/S200018

KVNSS Viswanadh

Viswanadh VNSS Kuchi

Partner

Membership No. 210789

Place: Hyderabad

Date: 28-January-2022

UDIN: *22210789AAAAA C6647*

